Adriana Marques

List of Publications by Year
in descending order

87 papers	6,782 citations	94381 37 h-index	60583 81 g-index
92 all docs	92 docs citations	92 times ranked	4858 citing authors

#	Article	IF	Citations
1	A Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. New England Journal of Medicine, 2005, 352, 2271-2284.	13.9	2,197
2	Varicellaâ€Zoster Virusâ€“Specific Immune Responses in Elderly Recipients of a Herpes Zoster Vaccine. Journal of Infectious Diseases, 2008, 197, 825-835.	1.9	329
3	Serodiagnosis of Lyme Disease by Kinetic Enzymeâ€Linked Immunosorbent Assay Using Recombinant VlsE1 or Peptide Antigens ofBorrelia burgdorferiCompared with 2â€Tiered Testing Using Wholeâ€Cell Lysates. Journal of Infectious Diseases, 2003, 187, 1187-1199.	1.9	261
4	Characterization and treatment of chronic active Epstein-Barr virus disease: a 28-year experience in the United States. Blood, 2011, 117, 5835-5849.	0.6	241
5	Long-term Persistence of Zoster Vaccine Efficacy. Clinical Infectious Diseases, 2015, 60, 900-909.	2.9	240
6	Identification of candidate T-cell epitopes and molecular mimics in chronic Lyme disease. Nature Medicine, 1999, 5, 1375-1382.	15.2	216
7	Persistence of the Efficacy of Zoster Vaccine in the Shingles Prevention Study and the Short-Term Persistence Substudy. Clinical Infectious Diseases, 2012, 55, 1320-1328.	2.9	203
8	Chronic Lyme Disease: A Review. Infectious Disease Clinics of North America, 2008, 22, 341-360.	1.9	158
9	Vaccination against Herpes Zoster and Postherpetic Neuralgia. Journal of Infectious Diseases, 2008, 197, S228-S236.	1.9	157
10	Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagnostic Microbiology and Infectious Disease, 2013, 75, 9-15.	0.8	137
11	Comprehensive Immunophenotyping of Cerebrospinal Fluid Cells in Patients with Neuroimmunological Diseases. Journal of Immunology, 2014, 192, 2551-2563.	0.4	130
12	Antibody Response to IR6, a Conserved Immunodominant Region of the VlsE Lipoprotein, Wanes Rapidly after Antibiotic Treatment ofBorrelia burgdorferiInfection in Experimental Animals and in Humans. Journal of Infectious Diseases, 2001, 184, 870-878.	1.9	121
13	Xenodiagnosis to Detect Borrelia burgdorferi Infection: A First-in-Human Study. Clinical Infectious Diseases, 2014, 58, 937-945.	2.9	111
14	Treatment Trials for Post-Lyme Disease Symptoms Revisited. American Journal of Medicine, 2013, 126, 665-669.	0.6	106
15	Laboratory Diagnosis of Lyme Disease. Infectious Disease Clinics of North America, 2015, 29, 295-307.	1.9	99
16	Comparison of Lyme Disease in the United States and Europe. Emerging Infectious Diseases, 2021, 27, 2017-2024.	2.0	99
17	A Longitudinal Study of COVID-19 Sequelae and Immunity: Baseline Findings. Annals of Internal Medicine, 2022, 175, 969-979.	2.0	99
18	Advances in Serodiagnostic Testing for Lyme Disease Are at Hand. Clinical Infectious Diseases, 2018, 66, 1133-1139.	2.9	82

#	Article	IF	Citations
19	Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain, 2003, 126, 20-31.	3.7	74
20	A multiplex serologic platform for diagnosis of tick-borne diseases. Scientific Reports, 2018, 8, 3158.	1.6	68
21	Lyme Disease: A Review. Current Allergy and Asthma Reports, 2010, 10, 13-20.	2.4	66
22	Long-Term Administration of Valacyclovir Reduces the Number of Epstein-Barr Virus (EBV)-Infected B Cells but Not the Number of EBV DNA Copies per B Cell in Healthy Volunteers. Journal of Virology, 2009, 83, 11857-11861.	1.5	62
23	Molecular Mimicry and Antigen-Specific T Cell Responses in Multiple Sclerosis and Chronic CNS Lyme Disease. Journal of Autoimmunity, 2001, 16, 187-192.	3.0	61
24	Direct Diagnostic Tests for Lyme Disease. Clinical Infectious Diseases, 2019, 68, 1052-1057.	2.9	60
25	Tick-borne Relapsing Fever andBorrelia hermsii, Los Angeles County, California, USA. Emerging Infectious Diseases, 2009, 15, 1026-1031.	2.0	58
26	Natural Killer Cell Counts Are Not Different between Patients with Post-Lyme Disease Syndrome and Controls. Vaccine Journal, 2009, 16, 1249-1250.	3.2	54
27	Invariant natural killer T cells act as an extravascular cytotoxic barrier for joint-invading Lyme Borrelia. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 13936-13941.	3.3	54
28	FLAIR and magnetization transfer imaging of patients with post-treatment Lyme disease syndrome. Neurology, 2001, 57, 1980-1985.	1.5	53
29	Cross-Species Interferon Signaling Boosts Microbicidal Activity within the Tick Vector. Cell Host and Microbe, 2016, 20, 91-98.	5.1	52
30	Protective Immunity and New Vaccines for Lyme Disease. Clinical Infectious Diseases, 2020, 70, 1768-1773.	2.9	50
31	Borrelia burgdorferiLipoproteinâ€“Mediated TLR2 Stimulation Causes the Downâ€Regulation of TLR5 in Human Monocytes. Journal of Infectious Diseases, 2006, 193, 849-859.	1.9	49
32	Rapid, Simple, Quantitative, and Highly Sensitive Antibody Detection for Lyme Disease. Vaccine Journal, 2010, 17, 904-909.	3.2	48
33	A Decline in C 6 Antibody Titer Occurs in Successfully Treated Patients with Culture-Confirmed Early Localized or Early Disseminated Lyme Borreliosis. Vaccine Journal, 2005, 12, 1069-1074.	3.2	46
34	Anti-Borrelia burgdorferi Antibody Profile in Post-Lyme Disease Syndrome. Vaccine Journal, 2011, 18, 767-771.	3.2	46
35	Long-term Follow-up of Patients With Lyme Disease: Longitudinal Analysis of Clinical and Quality-of-life Measures. Clinical Infectious Diseases, 2016, 62, 1546-1551.	2.9	46
36	C 6 Test as an Indicator of Therapy Outcome for Patients with Localized or Disseminated Lyme Borreliosis. Journal of Clinical Microbiology, 2003, 41, 4955-4960.	1.8	42

#	Article	IF	Citations
37	Pre-treatment and post-treatment assessment of the C6 test in patients with persistent symptoms and a history of Lyme borreliosis. European Journal of Clinical Microbiology and Infectious Diseases, 2004, 23, 615-8.	1.3	38
38	Lack of Evidence ofBorreliaInvolvement in Alzheimer's Disease. Journal of Infectious Diseases, 2000, 182, 1006-1007.	1.9	37
39	Epitope mapping of antibodies to VlsE protein of Borrelia burgdorferi in post-Lyme disease syndrome. Clinical Immunology, 2011, 141, 103-110.	1.4	36
40	Safety of Zoster Vaccine in Elderly Adults Following Documented Herpes Zoster. Journal of Infectious Diseases, 2013, 208, 559-563.	1.9	36
41	Insights into Borrelia miyamotoi infection from an untreated case demonstrating relapsing fever, monocytosis and a positive C6 Lyme serology. Diagnostic Microbiology and Infectious Disease, 2016, 86, 93-96.	0.8	35
42	Transcriptome Assessment of Erythema Migrans Skin Lesions in Patients With Early Lyme Disease Reveals Predominant Interferon Signaling. Journal of Infectious Diseases, 2018, 217, 158-167.	1.9	34
43	Revisiting the Lyme Disease Serodiagnostic Algorithm: the Momentum Gathers. Journal of Clinical Microbiology, 2018, 56, .	1.8	34
44	Suppurative Cutaneous Granulomata Caused by Microascus cinereus in a Patient with Chronic Granulomatous Disease. Clinical Infectious Diseases, 1995, 20, 110-114.	2.9	30
45	Plasticity in early immune evasion strategies of a bacterial pathogen. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E3788-E3797.	3.3	29
46	A Multiplexed Serologic Test for Diagnosis of Lyme Disease for Point-of-Care Use. Journal of Clinical Microbiology, 2019, 57, .	1.8	27
47	Lack of association between HSV-1 DNA in the brain, Alzheimer's disease and apolipoprotein E4. Journal of NeuroVirology, 2001, 7, 82-83.	1.0	26
48	Borrelia burgdorferiInduces TLR1 and TLR2 in Human Microglia and Peripheral Blood Monocytes but Differentially Regulates HLA-Class II Expression. Journal of Neuropathology and Experimental Neurology, 2006, 65, 540-548.	0.9	26
49	IL-10 Helps Control Pathogen Load during High-Level Bacteremia. Journal of Immunology, 2008, 181, 2076-2083.	0.4	26
50	Expression of C-Reactive Protein and Serum Amyloid A in Early to Late Manifestations of Lyme Disease. Clinical Infectious Diseases, 2016, 63, 1399-1404.	2.9	26
51	Identification of immunoreactive linear epitopes of Borrelia miyamotoi. Ticks and Tick-borne Diseases, 2020, 11, 101314.	1.1	25
52	Culture of Borrelia burgdorferi. Journal of Clinical Microbiology, 2001, 39, 2747-2747.	1.8	22
53	Cerebrospinal Fluid-Infiltrating CD4 + T Cells Recognize Borrelia burgdorferi Lysine-Enriched Protein Domains and Central Nervous System Autoantigens in Early Lyme Encephalitis. Infection and Immunity, 2007, 75, 243-251.	1.0	22
54	Evaluation of the C6 Peptide Enzyme-Linked Immunosorbent Assay for Individuals Vaccinated with the Recombinant OspA Vaccine. Journal of Clinical Microbiology, 2002, 40, 2591-2593.	1.8	20

#	Article	IF	Citations
55	High Production of CXCL13 in Blood and Brain During Persistent Infection With the Relapsing Fever Spirochete Borrelia turicatae. Journal of Neuropathology and Experimental Neurology, 2007, 66, 208-217.	0.9	20
56	Role of Interleukin 10 during Persistent Infection with the Relapsing Fever Spirochete Borrelia turicatae. American Journal of Pathology, 2007, 170, 251-262.	1.9	20
57	Synthesis and antigenicity of BBGL-2 glycolipids of Borrelia burgdorferi, the causative agent of Lyme disease. Carbohydrate Research, 2011, 346, 1551-1563.	1.1	20
58	Epitope-Specific Evolution of Human B Cell Responses toBorrelia burgdorferiVlsE Protein from Early to Late Stages of Lyme Disease. Journal of Immunology, 2016, 196, 1036-1043.	0.4	20
59	Detection of Immune Complexes Is Not Independent of Detection of Antibodies in Lyme Disease Patients and Does Not Confirm Active Infection with Borrelia burgdorferi. Vaccine Journal, 2005, 12, 1036-1040.	3.2	19
60	Audiologic Manifestations of Patients with Post-Treatment Lyme Disease Syndrome. Ear and Hearing, 2003, 24, 508-517.	1.0	16
61	Early Disseminated Lyme Disease Causing False-Positive Serology for Primary Epstein-Barr Virus Infection: Report of 2 Cases. Clinical Infectious Diseases, 2017, 65, 336-337.	2.9	12
62	Characteristics and outcome of facial nerve palsy from Lyme neuroborreliosis in the United States. Annals of Clinical and Translational Neurology, 2022, 9, 41-49.	1.7	12
63	Antiphospholipid autoantibodies in Lyme disease arise after scavenging of host phospholipids by Borrelia burgdorferi. Journal of Clinical Investigation, 2022, 132, .	3.9	12
64	Herpes simplex type 2 infectionsâ€"An update. Disease-a-Month, 2000, 46, 325-359.	0.4	11
65	Interleukin 10 Protects the Brain Microcirculation From Spirochetal Injury. Journal of Neuropathology and Experimental Neurology, 2008, 67, 976-983.	0.9	11
66	Usefulness of Routine Lyme Screening in Patients with Uveitis. Ophthalmology, 2019, 126, 1726-1728.	2.5	11
67	C-Reactive Protein Response in Patients With Post-Treatment Lyme Disease Symptoms Versus Those With Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Clinical Infectious Diseases, 2018, 67, 1309-1310.	2.9	10
68	Post-treatment Lyme disease symptoms score: Developing a new tool for research. PLoS ONE, 2019, 14, e0225012.	1.1	10
69	Lyme disease: An update. Current Allergy and Asthma Reports, 2001, 1, 541-549.	2.4	9
70	Relapsing Fever Borreliosis in Interleukin-10-Deficient Mice. Infection and Immunity, 2008, 76, 5508-5513.	1.0	9
71	Development of a capture sequencing assay for enhanced detection and genotyping of tick-borne pathogens. Scientific Reports, 2021, 11, 12384.	1.6	9
72	Advances in the treatment of chronic hepatitis B virus infection. , 1998, 8, 223-234.		7

#	Article	IF	Citations
73	Lack of Serum Antibodies against Borrelia burgdorferi in Children with Autism. Vaccine Journal, 2013, 20, 1092-1093.	3.2	6
74	Characterization of a Monanema nematode in Ixodes scapularis. Parasites and Vectors, 2020, 13, 371.	1.0	6
75	A RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF REPEATED IV ANTIBIOTIC THERAPY FOR LYME ENCEPHALOPATHY PROLONGED LYME DISEASE TREATMENT: ENOUGH IS ENOUGH. Neurology, 2009, 72, 383-386.	1.5	5
76	Is there a place for xenodiagnosis in the clinic?. Expert Review of Anti-Infective Therapy, 2014, 12, 1307-1310.	2.0	5
77	Association of Immune Response to Endothelial Cell Growth Factor With Early Disseminated and Late Manifestations of Lyme Disease but Not Posttreatment Lyme Disease Syndrome: Figure 1.. Clinical Infectious Diseases, 2015, 61, civ638.	2.9	5
78	Natural Killer Cells in Chronic Lyme Disease. Vaccine Journal, 2009, 16, 1704-1706.	3.2	4
79	Xenodiagnosis Using Ixodes scapularis Larval Ticks in Humans. Methods in Molecular Biology, 2018, 1690, 337-346.	0.4	3
80	Citrate Anticoagulant Improves the Sensitivity of Borreliella (Borrelia) burgdorferi Plasma Culture. Journal of Clinical Microbiology, 2017, 55, 3297-3299.	1.8	2
81	Lack of Convincing Evidence that Borrelia burgdorferi Infection Causes Either Alzheimerâ€™s Disease or Lewy Body Dementia. Clinical Infectious Diseases, 2021, , .	2.9	2
82	Reply to von Reyn and Horsburgh. Clinical Infectious Diseases, 2018, 67, 1308-1309.	2.9	1
83	Detection of antibodies to Anaplasma phagocytophilum and Babesia microti using linear peptides. Ticks and Tick-borne Diseases, 2022, 13, 101999.	1.1	1
84	IL-10 protects the cerebral microcirculation from spirochetal injury. Journal of Neuropathology and Experimental Neurology, 2007, 66, 432.	0.9	0
85	1348Immune response to endothelial cell growth factor is elevated during acute Lyme borreliosis but not in post-Lyme disease syndrome. Open Forum Infectious Diseases, 2014, 1, S353-S353.	0.4	0
86	1352Progression of Lyme Disease to Later Stages is Associated with Antibody Response Towards the Membrane-Proximal Domain of the VlsE Protein of Borrelia burgdorferi. Open Forum Infectious Diseases, 2014, 1, S354-S354.	0.4	0
87	The Reply. American Journal of Medicine, 2014, 127, e11-e12.	0.6	0